Genentech

Pharma

Roche's Enspryng muscles in on Tepezza's TED turf

Some six years after scoring an initial FDA nod, Roche’s IL-6 receptor inhibitor Enspryng is muscling up to Amgen's Tepezza in a key eye disease arena.

Fraiser Kansteiner Oct 16, 2026 9:26am

Genentech opens its history books in 50 year anniversary doc

Oct 6, 2026 9:00am

Genentech amplifies breast cancer conversations in new campaign

Oct 1, 2026 2:52pm

pivot change turnaround direction walk away

Roche's Gazyva secures FDA nod in 2nd autoimmune indication

Sep 28, 2026 2:29pm

Genentech CMO Zoë Lazarre uses AI as a 'digital backpack'

Sep 22, 2026 2:57pm

Roche reports positive confirmatory trial readout for Lunsumio

Sep 17, 2026 11:25am